ZIVO BIOSCIENCE INC | 10-Q: FY2025 Q1 Revenue: USD 0

Revenue: As of FY2025 Q1, the actual value is USD 0.

EPS: As of FY2025 Q1, the actual value is USD -1.12.

EBIT: As of FY2025 Q1, the actual value is USD -4.209 M.

Segment Revenue

• Total Revenues: For the three months ended March 31, 2025, Zivo Bioscience, Inc. recorded no revenue, compared to $35,720 for the same period in 2024, due to no product orders from the exclusive distributor.

Operational Metrics

• Net Loss: The net loss for the three months ended March 31, 2025, was $4,211,188, compared to $1,278,486 for the same period in 2024.
• General and Administrative Expenses: Increased to $1,439,552 in 2025 from $975,574 in 2024, primarily due to higher professional fees.
• Research and Development Expenses: Increased significantly to $2,769,236 in 2025 from $312,767 in 2024, largely due to costs associated with extinguishing Participation Agreements.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was - $1,430,238 for the three months ended March 31, 2025, compared to - $1,699,118 for the same period in 2024.
• Financing Activities: Generated $404,985 in 2025, a decrease from $1,563,379 in 2024, due to the absence of funds raised through sales of common stock in 2025.

Future Outlook and Strategy

• Core Business Focus: Zivo Bioscience, Inc. plans to continue developing bioactive compounds from its proprietary algal culture, targeting diseases such as poultry coccidiosis and bovine mastitis, and seeks strategic partners for late-stage development and commercialization.
• Non-Core Business: The company is exploring additional indications such as avian influenza and canine joint health, pending additional funding.
• Funding Requirements: The company acknowledges substantial doubt about its ability to continue as a going concern and requires approximately $5 million in cash over the next 12 months to fund basic operations, excluding R&D initiatives.